Amylyx Pharmaceuticals (AMLX) Competitors $9.38 -0.04 (-0.42%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.38 0.00 (0.00%) As of 08/29/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. KYMR, AMRX, XENE, ARWR, VKTX, CRNX, RARE, MOR, NAMS, and HCMShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Kymera Therapeutics (KYMR), AMNEAL PHARMACEUTICALS (AMRX), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), NewAmsterdam Pharma (NAMS), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Its Competitors Kymera Therapeutics AMNEAL PHARMACEUTICALS Xenon Pharmaceuticals Arrowhead Pharmaceuticals Viking Therapeutics Crinetics Pharmaceuticals Ultragenyx Pharmaceutical MorphoSys NewAmsterdam Pharma HUTCHMED Kymera Therapeutics (NASDAQ:KYMR) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Is KYMR or AMLX more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-616.03% -31.60% -27.12% Amylyx Pharmaceuticals N/A -82.48%-70.15% Do institutionals & insiders believe in KYMR or AMLX? 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, KYMR or AMLX? Kymera Therapeutics has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500. Do analysts prefer KYMR or AMLX? Kymera Therapeutics currently has a consensus price target of $58.76, indicating a potential upside of 42.63%. Amylyx Pharmaceuticals has a consensus price target of $12.25, indicating a potential upside of 30.60%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Kymera Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 3.11Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, KYMR or AMLX? Kymera Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M62.58-$223.86M-$3.47-11.87Amylyx Pharmaceuticals$87.37M9.57-$301.74M-$2.50-3.75 Does the media prefer KYMR or AMLX? In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 7 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.57 beat Amylyx Pharmaceuticals' score of 0.80 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amylyx Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryKymera Therapeutics beats Amylyx Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$836.39M$2.80B$5.75B$9.76BDividend YieldN/A1.58%4.08%4.04%P/E RatioN/A22.8083.2726.60Price / Sales9.57737.53541.17113.73Price / CashN/A174.6137.4459.26Price / Book3.915.9810.556.58Net Income-$301.74M$32.94M$3.27B$265.95M7 Day Performance0.86%-1.28%0.40%0.17%1 Month Performance16.81%5.64%7.31%3.90%1 Year Performance322.52%-3.15%46.58%19.67% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals3.4323 of 5 stars$9.38-0.4%$12.25+30.6%+322.5%$836.39M$87.37M0.00200News CoverageAnalyst ForecastKYMRKymera Therapeutics3.0252 of 5 stars$41.82-5.2%$59.11+41.3%-14.8%$3.15B$47.07M0.00170News CoveragePositive NewsAMRXAMNEAL PHARMACEUTICALS3.5865 of 5 stars$9.28-3.2%$11.60+25.0%+10.4%$3.01B$2.79B14.318,100Positive NewsInsider TradeXENEXenon Pharmaceuticals2.2807 of 5 stars$38.14-1.8%$53.20+39.5%-4.0%$2.99B$9.43M0.00210Positive NewsARWRArrowhead Pharmaceuticals3.6892 of 5 stars$20.71-2.9%$43.14+108.3%-7.6%$2.95B$3.55M-16.18400News CoveragePositive NewsVKTXViking Therapeutics3.883 of 5 stars$25.85-0.6%$86.92+236.3%-57.8%$2.92BN/A-16.9020Analyst RevisionCRNXCrinetics Pharmaceuticals3.7129 of 5 stars$30.09-2.7%$68.86+128.8%-41.6%$2.91B$1.04M-7.32210News CoveragePositive NewsInsider TradeRAREUltragenyx Pharmaceutical4.6323 of 5 stars$29.27-1.7%$81.50+178.4%-47.2%$2.87B$560.23M-5.291,294MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730NAMSNewAmsterdam Pharma3.5759 of 5 stars$24.70-1.2%$41.55+68.2%+46.5%$2.82B$45.56M0.004Insider TradeHCMHUTCHMED2.4231 of 5 stars$15.93-1.1%$28.00+75.8%-14.0%$2.81B$630.20M0.001,811Analyst Upgrade Related Companies and Tools Related Companies Kymera Therapeutics Competitors AMNEAL PHARMACEUTICALS Competitors Xenon Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Viking Therapeutics Competitors Crinetics Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors MorphoSys Competitors NewAmsterdam Pharma Competitors HUTCHMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMLX Stock Alerts